Navigation Links
Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
Date:4/14/2008

have compromised HRR and may be particularly sensitive to SNS-595.

Data from these nonclinical studies of SNS-595 were presented today at the AACR Annual Meeting in three posters:

-- SNS-595 is a potent anti-tumor agent that has a dual mechanism of

action: DNA intercalation and site-selective topoisomerase II poisoning

[Abstract #1860]

-- Ex vivo activity of SNS-595 against biopsies of acute myeloid leukemia,

triple negative breast and ovarian cancers supports ongoing and

potential clinical [Abstract #2830]

-- Sensitivity to SNS-595 is related to activation of double strand DNA

break repair pathways including homologous recombination

[Abstract #1859]

SNS-595 is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously in the treatment of cancer.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential efficacy, mechanism of action and benefits of SNS-595, and the potential for SNS-595 to be tested in other indications. Words such as "may," "potential," "could"
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
2. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
6. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
7. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Aquarium Research Institute (MBARI) have observed a deep-sea octopus ... than any other known animal. Throughout this time, the ... predators. This amazing feat represents an evolutionary balancing act ... plenty of time to develop within their eggs, and ... or no food. , Every few months for the ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... who were breastfed for three months or more ... chronic inflammation associated with cardiovascular and metabolic diseases, ... Washington University in St. Louis. , "This study ... for children,s health decades later," said Molly W. ... and a co-author of the study with Thomas ...
(Date:7/30/2014)... ‚ÄúToday, we have said ¡Basta! (enough) to the ... to our children and our families. The SWEET Act ... to put the health of people first and make ... President and CEO of the National Alliance for Hispanic ... (SWEET) Act by Congresswoman Rosa L. DeLauro. , The ...
(Date:7/30/2014)... With the recent May 21st opening of the ... Museum Workshop in the Meatpacking District has been encountering some ... Carole Barnes, "We have had to re-write the description of ... who sell us so tourists don't confuse the two 9/11 ... we do and what the new Museum does in terms ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... the Division of Allergy and Immunology at Cincinnati ... extend funding of his long-standing investigation into "Regulation ... award from the National Institute of Allergy and ... of research accomplishment." Eosinophilic disorders occur ...
... HealthDay Reporter , THURSDAY, July 22 (HealthDay News) ... a result of taking statins don,t seem to benefit from ... The conventional wisdom has been that to reduce the ... LDL, or "bad," cholesterol and increase your HDL, or ...
... specific brain regions in female patients with irritable bowel syndrome ... abdomen, along with diarrhea, constipation or both. ... the study appears in the July issue of the journal ... IBS is associated with both decreases and increases in grey ...
... include certain must-have vitamins in their diets to stave off ... Alberta. , A study of 43 children and teens ... disease showed that they also tended to have low bone ... and minerals. That means they should be getting more of ...
... study into the causes of deaths of workers at ... rates from all causes and cancer in general when ... known by occupational health researchers as the "healthy worker ... such as leukemia or multiple myeloma were slightly above ...
... total joint replacement registry based on carefully designed and ... cost-effectiveness and research, according to a paper published in ... and Related Research , a journal of the Association ... Total Joint Replacement Registry the nation,s largest such registry ...
Cached Medicine News:Health News:Doctor at Cincinnati Children's receives prestigious NIH MERIT Award 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 3Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Study describes health effects of occupational exposures in Paducah Gaseous Diffusion Plant workers 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
... High Productivity, improved safety and lower cost per ... solution to sample prep bottlenecks in the busy ... amazingly compact and quiet centrifuge spins standard 5 ... yet it produces quality serum or plasma equal ...
The StatSpin Express 3 provides faster turnaround time and greater productivity for your laboratory....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: